Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

Destiny reminded me about Abuse deterrent properties for generic oxy. Completely spaced on that.

I’d love to see a 10% capture rate for the generic portion of the total CNS market. I think it’s highly unlikely with the aggressive competition. Assume conservatively and best expectations. Hands down they have done amazingly well with Adderall IR.

Lannett could barely sell ER. Our contract with Prasco will be sweet, but it is a 2-year contract. Might be extended, might not. API getting relaxed will open more doors for Elite’s ER too. This is a huge untapped market for Elite.

Vyvanse coming off patent I think has 12+ generic manufacturers already approved. It is a huge market, but it’s also swimming in a shark tank. There will be plenty of opportunity for Elite. Will we capture 5%? I think we can. 10% would be a stretch. Nothing would make me happier than if we do execute at that level. We’ll need much more mfg & storage space…